336 related articles for article (PubMed ID: 24840521)
21. Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1
Lin MY; Damron TA; Horton JA
Int J Radiat Biol; 2023; 99(10):1570-1583. PubMed ID: 36913323
[TBL] [Abstract][Full Text] [Related]
22. Targeting the DNA repair pathway in Ewing sarcoma.
Stewart E; Goshorn R; Bradley C; Griffiths LM; Benavente C; Twarog NR; Miller GM; Caufield W; Freeman BB; Bahrami A; Pappo A; Wu J; Loh A; Karlström Å; Calabrese C; Gordon B; Tsurkan L; Hatfield MJ; Potter PM; Snyder SE; Thiagarajan S; Shirinifard A; Sablauer A; Shelat AA; Dyer MA
Cell Rep; 2014 Nov; 9(3):829-41. PubMed ID: 25437539
[TBL] [Abstract][Full Text] [Related]
23. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
[TBL] [Abstract][Full Text] [Related]
24. A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.
Ramos L; Truong S; Zhai B; Joshi J; Ghaidi F; Lizardo MM; Shyp T; Kung SHY; Rezakhanlou AM; Oo HZ; Adomat H; Le Bihan S; Collins C; Bacha J; Brown D; Langlands J; Shen W; Lallous N; Sorensen PH; Daugaard M
Clin Cancer Res; 2023 Sep; 29(17):3541-3553. PubMed ID: 37279093
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
28. The role of PARP in DNA repair and its therapeutic exploitation.
Javle M; Curtin NJ
Br J Cancer; 2011 Oct; 105(8):1114-22. PubMed ID: 21989215
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
He JX; Yang CH; Miao ZH
Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.
Zaremba T; Thomas H; Cole M; Plummer ER; Curtin NJ
Cancer Chemother Pharmacol; 2010 Sep; 66(4):807-12. PubMed ID: 20490796
[TBL] [Abstract][Full Text] [Related]
31. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
32. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
Vormoor B; Schlosser YT; Blair H; Sharma A; Wilkinson S; Newell DR; Curtin N
Oncotarget; 2017 Dec; 8(69):113418-113430. PubMed ID: 29371919
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Peralta-Leal A; Rodríguez MI; Oliver FJ
Clin Transl Oncol; 2008 Jun; 10(6):318-23. PubMed ID: 18558578
[TBL] [Abstract][Full Text] [Related]
34. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
39. Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin.
Lee SG; Kim N; Kim SM; Park IB; Kim H; Kim S; Kim BG; Hwang JM; Baek IJ; Gartner A; Park JH; Myung K
EMBO Rep; 2020 Nov; 21(11):e48676. PubMed ID: 33006225
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]